279 related articles for article (PubMed ID: 20862748)
1. Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C
Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Hariharan S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Nieto A; Yuan J; Bukowski R
Lancet Oncol; 2009 Aug; 10(8):757-63. PubMed ID: 19615940
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.
Chevreau C; Ravaud A; Escudier B; Amela E; Delva R; Rolland F; Tosi D; Oudard S; Blanc E; Ferlay C; Négrier S;
Clin Genitourin Cancer; 2014 Feb; 12(1):50-4. PubMed ID: 24268852
[TBL] [Abstract][Full Text] [Related]
6. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Hawkins RE; Crinò L; Kim TM; Carteni G; Eberhardt WE; Zhang K; Fly K; Matczak E; Lechuga MJ; Hariharan S; Bukowski R
Br J Cancer; 2015 Jun; 113(1):12-9. PubMed ID: 26086878
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy.
Lim ZD; Mahajan A; Weinberg J; Tannir NM
Am J Clin Oncol; 2013 Jun; 36(3):258-60. PubMed ID: 22441343
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
10. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
Vrdoljak E; Géczi L; Mardiak J; Ciuleanu TE; Leyman S; Zhang K; Sajben P; Torday L
Pathol Oncol Res; 2015 Jul; 21(3):775-82. PubMed ID: 25557271
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in metastatic renal cell carcimoma: a single-center experience.
Krishna VM; Noronha V; Prabhash K; Joshi A; Patil V; Bhosale B; Ravi T; Menon H; Gupta S; Banavali SD; Bakshi G; Tangaonkar HB
Indian J Cancer; 2013; 50(3):268-73. PubMed ID: 24061470
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
Yildiz I; Ekenel M; Akman T; Kocar M; Uysal M; Kanitez M; Varol U; Bayoglu IV; Tural D; Kaplan MA; Avci N; Sürmeli Z; Dede İ; Ulaş A; Yazici O; Basaran M
Anticancer Res; 2014 Aug; 34(8):4329-34. PubMed ID: 25075067
[TBL] [Abstract][Full Text] [Related]
20. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
